Skip Over Navigation Links

Answers to Frequently Asked Questions About MIRA RFA-GM-16-002

NOTE: The FOA lists the earliest award date as December 2016.  This is an error.  The earliest award date is actually April 2016.

I. Funding Opportunity Description

II. Award Information

III. Eligibility Information

IV. Application and Submission Information

V. Review Information

VI. Award Administration Information (Including Funding Restrictions in Section IV.2 of the FOA)

I. Funding Opportunity Description

Q.  What is the NIGMS MIRA program and what is its purpose?

A. The Maximizing Investigators' Research Award (MIRA) is an experiment to test the concept of support for an investigator and his/her laboratory as a whole, rather than on a project-by-project basis. Its purpose is to provide support for the NIGMS mission-relevant research in the laboratory through a single grant award. The anticipated advantages of this approach include:  increased stability of funding; enhanced ability to take on ambitious scientific projects and approach problems creatively; increased flexibility to follow important new research directions as opportunities arise; more widely distributed funding among investigators; increased efficiency and efficacy of NIGMS funding; increased productivity and improved chances for important breakthroughs; reduced time spent writing, reviewing and managing multiple research grants; and more time for conduct of research and mentoring junior scientists in a more stable environment.

Q.  What distinguishes MIRA from traditional NIH programs?

A. The key differences are: the scope of the research supported by the MIRA, which encompasses all NIGMS-mission relevant research in the PI's laboratory, rather than a single, narrowly-focused project; the flexibility that this will provide to the investigator to pursue new research directions as opportunities arise; a reduced level of detail required in the application, including the elimination of specific aims; differences in the review process and review criteria to emphasize the impact of the work and to de-emphasize details of the approach; enhanced success rates and planned modulation of budgets during renewals, rather than abrupt termination of laboratory support. 

Q.  How much time/effort must recipients devote to MIRA? How many calendar months?

A. Investigators must devote 51 percent of their research effort, i.e., not including effort expended toward teaching, administration and/or clinical duties. So, for example, if an investigator spends 50 percent of his or her time in the clinic and the rest on research, he or she must devote more than 25 percent effort to MIRA, regardless of the amount of salary support requested. Investigators cannot simultaneously hold another award that requires greater than or equal to 50 percent research effort. The number of calendar months of commitment (summer, academic or annual) equivalent to a 51 percent commitment depends on what fraction of 12 months is devoted to research. For the example above, this would be greater than or equal to 3 months. Because of reporting system limits, this may need to be rounded to the nearest whole month.

Q.  What scientific areas of research are appropriate for support by MIRA?

A. Any research area within the mission of NIGMS is eligible for support using the MIRA award. Research areas supported by NIGMS are outlined on the NIGMS Web site. However, some types of research might be more suitably supported using a traditional R01 or other grant mechanism with more specific detail provided (e.g., clinical trials). See the NIH definition of a clinical trial at NIGMS offers other mechanisms to support clinical trials.

Q.  Can technology development be included or is the award only for hypothesis-driven research?

A. Yes. Technology development can be an essential part of any research program and hypothesis-driven science is only one way of approaching a research problem. 

Q.  Can I continue to work with my current collaborators, including foreign collaborators?

A. Yes. NIGMS strongly endorses collaborative research. However, the MIRA concept is based on the idea that NIGMS will provide support to individual investigators and their laboratories. Collaborators will work together because of their mutual interest in a problem, not through a subcontract. This applies to foreign collaborations as well. NIGMS will accept applications with a foreign collaboration, but will not provide funding for foreign consortium arrangements.

Q.  Can you clarify how much flexibility is meant by "flexibility to pursue new research directions"?

A. This needs to be considered on a case-by-case basis with the application of reasonable judgment by both investigators and NIGMS staff. The extension of studies on a problem from one organism to another would be very reasonable. Insights gained from studying one biological problem that extend the project into another within the mission of NIGMS would also be reasonable. When in doubt, it may be useful to discuss changes with an NIGMS program director. 

Q.  What will be considered in scope and what would be out of the scope of MIRA?

A. Changes in scope would include the addition of or a change in the approved use of human subjects, vertebrate animals, select agents or hESCs and would require prior approval by NIGMS before the work is initiated. However, such changes in scope can be approved with appropriate documentation. Work that migrates fully into the mission of another NIH institute or center would be considered out of scope and it would be appropriate for this work to transition out of MIRA to the relevant other NIH institute or center.

Q.  How can I decide if MIRA is right for my circumstances?

A. Ask yourself how much time and effort it takes you to maintain the current NIGMS funding of your laboratory through multiple, separate grant applications. Decide whether consolidation of your projects at something close to your average level of NIGMS support is worth the advantages provided by the MIRA program, which includes 5 years of funding and a higher probability of successful renewal.

Q.  Why does NIGMS think that this initiative will enhance the quality of science generated by its community of grantees?

A. MIRA-supported investigators will have the flexibility to pursue the science they want to do as it evolves, rather than being held to specific aims that they proposed before they received a grant. In this way, they will have greater flexibility to try ideas that might be considered high risk. MIRA will result in more stable funding of investigators, better continuity of effort and better ability to keep well-trained personnel in the laboratory. MIRA will broaden the distribution of funding among laboratories, enabling more of the nation's highly talented and promising investigators to participate.

II. Award Information

Q.  How many MIRAs does NIGMS expect to award in FY 2016?

A. This depends on how many meritorious applications are received from eligible investigators. NIGMS estimates that as many as 100 awards will be made.

Q.  What is the anticipated success rate for this FOA?

A. This depends on the quality of the applications and the outcomes of the review process. It is difficult to predict, but given that these are already ongoing awards, the MIRA success rate is expected to be higher than that typical for NIGMS R01 applications.

Q.  What is the anticipated average award size for this FOA?

A. This depends on the current funding levels of the eligible investigators who apply for MIRA, their budget requests and the recommendations of study sections, the National Advisory General Medical Sciences Council and NIGMS staff.

Q.  What is the maximum allowable budget?

A. Applications may request up to $750,000 in direct costs per year for a period of 5 years. However, investigators are expected to request what is actually well-justified for their research program. In general, the request should be commensurate with the investigator's current total NIGMS research funding. Cost efficiency is one of the goals of the MIRA program and will be one of the considerations in review and funding decisions.

III. Eligibility Information

Q.  Who is eligible to apply? Can you work through some examples?

A. This initial FOA is intended to test the MIRA concept in a carefully controlled way with a well-defined, manageably-sized cohort of potential applicants. The participation of this group of applicants in the MIRA program is also important to the overall ability of the initiative to achieve its goals.

This FOA targets investigators who received either two or more R01 equivalent awards (defined here as R01, R37, DP1 or DP2 awards), or a single award of greater than $400,000 in direct costs, from NIGMS in FY 2013 or FY 2014 (i.e., October 1, 2012 - September 30, 2013, or October 1, 2013 – September 30, 2014), and with support for one or more of their awards expiring in FY 2016 or FY 2017 (i.e., October 1, 2015 - September 30, 2016, or October 1, 2016 - September 30, 2017). Other investigators are ineligible.

What counts as having received two or more NIGMS awards in FY 2013 or FY 2014? Does that mean competing or noncompeting awards? Does it include grants in no-cost extension status?

An institution should have received a competing, noncompeting or supplemental notice of grant award in FY 2013 (October 1, 2012 - September 30, 2013) or FY 2014 (October 1, 2013 - September 30, 2014) with the applicant investigator as the PI. 

What about having one or more projects due to expire in FY 2016 or FY 2017? Is this a requirement or not? What about investigators with projects expiring in FY 2015?

At least one grant should remain active in FY 2015 with an expiration date in FY 2016 (October 1, 2015 - September 30, 2016) or FY 2017 (Oct 1, 2016 - September 30, 2017). 

The stipulation of having a grant due to expire in FY 2016 or FY 2017 is to facilitate the transition of investigators from their current R01-type grant support to MIRA support without a lapse in funding.  The inclusion of two fiscal years is to provide a long lead time over which plans for relinquishing current funding may be negotiated and implemented. Grants in a no cost extension remain active and expire at the end of the no cost extension period.

Why are U01s being excluded from eligibility consideration?

U01s involve substantial NIH staff involvement. It is unclear how that involvement will be incorporated into MIRA. Since this is a limited test of the MIRA concept, the inclusion of U01s was not considered necessary to achieve the desired number of eligible applicants.

If I am a PI on a single PI R01 and a multi-PI R01, am I eligible to apply?

Yes, but see VI. Award Administration Information.

If I am a PI on two multi-PI R01s, am I eligible to apply?

Yes, but see VI. Award Administration Information.

If I am a PI on two R01s and a P01 subproject, am I eligible to apply?

Yes, but see VI. Award Administration Information.

If I am a PI on a R01 and a P01 subproject, am I eligible to apply? 

No, not at this time.

Q.  Are individuals at all stages of their careers eligible?

A. This FOA targets established investigators with two or more awards from NIGMS or one award over $400,000 in direct costs. NIGMS anticipates issuing additional FOAs in the future for which other groups of investigators will be eligible.

Q.  May two or more scientists apply as a team for an NIGMS MIRA?

A. This FOA is an initial test of the MIRA concept. It is intended to provide support for the research program of a single independent, established investigator. In the future, NIGMS may issue additional FOAs broadening eligibility to include multiple-PI programs of research where the contributions of the investigators are so entwined that it is not possible to separate them.

Q.  Are women and members of underrepresented groups encouraged to apply?

A. Women and members of underrepresented groups who meet the other eligibility requirements are strongly encouraged to apply. 

Q.  Are scientists in the NIH intramural research program eligible to apply?

A. NIH intramural research program scientists are not eligible to apply. A MIRA application can include a collaboration with an intramural scientist, but no funds can be provided to the intramural laboratory via MIRA. MIRA will not be converted to a cooperative agreement. Therefore, if involvement with an intramural lab is a substantial part of the investigator's research program, MIRA may not be a suitable means of support.

Q.  Are individuals who have support from sources other than NIGMS eligible to apply?

A. Yes. Individuals may have support from other NIH components or from other sources, provided they meet the eligibility requirement of having received at least two awards from NIGMS (R01, R37, DP1 or DP2) or one award over in $400,000 direct costs per year. However, they must be able to accommodate the requirement that they commit 51 percent of their research effort to MIRA. Also note that the level of outside support will be taken into account in determining the MIRA budget.

Q.  Can I submit an application for continuation of my current NIGMS grant support and apply for MIRA at the same time?

A. No. NIH policy prohibits the submission of two applications on the same subject at the same time. An investigator must have received the summary statement for a currently pending application before submitting another application on the same topic. For example, if a PI submits a continuation of his or her current R01 on March 5, 2015, he or she would not be able to submit a MIRA later on May 20, 2015.  If the PI submits a MIRA application on May 20, 2015, then he or she would not be able to submit a continuation of his or her current R01 until February/March 2016. However, even with this delay, he or she could still receive either the MIRA or a continuation of his or her R01 by the end of FY 2016 (September 30, 2016).

Q.  Are Howard Hughes Medical Institute investigators eligible to apply for MIRA? What about individuals with other types of substantial, unrestricted laboratory grant support?

A. Yes. HHMI investigators are eligible to apply for MIRA. The relationship between the work supported by HHMI and the work to be supported by NIGMS must be carefully explained, but need not be separated into different projects and different specific aims. However, study sections, the National Advisory General Medical Sciences Council and NIGMS staff will take total support, including PI salary support by HHMI, into account when considering the appropriate budget level of MIRA. Investigators with other types of substantial, unrestricted laboratory support will be similarly considered on a case-by-case basis.

Q.  If I have an appointment at more than one institution, can I apply for a separate MIRA through each institution?

A. No. An investigator can only receive one MIRA award, which should be submitted by the institution where he or she primarily conducts his or her research program. Under rare circumstances, a subcontract might be permitted to support a part of the research program that is based at a different domestic institution.

Q.  Can I get a definitive determination of my eligibility prior to submitting an application to this Request for Application (RFA)?

A. No. NIGMS staff can give you advice on eligibility. However, applications are received by the Receipt and Referral Office of the NIH Center for Scientific Review, and it is the responsibility of this office to assess eligibility based on the criteria stated in the FOA.

IV. Application and Submission Information

Q.  Is there a limit on the number of applications that can be submitted by an institution? By a PI?

A. There is no limit on the number of applications that can be submitted by an institution, provided they are for support of the research programs of different independent investigators. A PI may submit only one application for MIRA.

Q.  Can I get advice on my ideas for submission of a MIRA application?

A. You may discuss your ideas with the program contact named in the FOA or with the program director(s) who administers your current NIGMS applications and awards.

Q.  What became of the specific aims section of the grant application?

A. Specific aims are not required because the goal of MIRA is to move the scientific enterprise away from a focus on narrowly defined projects with highly tailored specific aims and to refocus attention on the big picture and overall impact of the research.

Q.  What format should the application follow?

A. Follow the instructions in the SF424 R&R application guide as modified by the instructions in the FOA.  In brief, this means that the scientific content of the application will rely mainly on the abstract, public health relevance statement, facilities and other resources page, biosketch and the six page research strategy, plus details on the involvement of human subjects and vertebrate animals as necessary. Avoid duplicating material covered in other sections. Do not include lists of publications, except as part of the biosketch, or references as necessary in the Bibliography & References Cited section of the Other Project Information Form. Provide current and pending research support information at the time of application using the format typically used for Just-in-Time information. Be sure to distinguish the direct costs per year that support research in the investigator's laboratory from support that goes to other investigators.

Why is the Research Strategy Section only six pages?

Because of changes in the biosketch, much of the needed information about the recent past research contributions of the investigator can be presented there, rather than in the research plan. Also because the goal of MIRA is to focus investigator and reviewer attention on the higher level questions about significance and impact of the research program, details in the research plan can be reduced. 

Q.  What may I include in the appendix?

A. Appendix materials are limited to the same items as for other NIH grant mechanisms. Do not use the appendix to circumvent the page limits. See NOT-OD-11-080.

Q.  Should I submit letters of support?

A. Letters of support should be included for all collaborators. The application must also include a letter from the institution's Authorized Organizational Official indicating that the institution is aware of and accepts the condition that other NIGMS research awards must be relinquished as a condition of receiving a MIRA award, and providing a statement that if chosen to receive an award, the PI will commit a minimum of 51 percent of his or her research effort to MIRA activities.

Q.  What is the policy on acceptance of late applications?

A. NIGMS will follow the recently announced NIH policy on the submission of late applications by investigators who serve on NIH study sections. See

Q.  Can I request money for equipment in the budget?

A. Yes. You may request money for equipment in the first year and in any subsequent years with appropriate justification. Bear in mind that such requests should be accommodated within a budget that is commensurate with the overall NIGMS grant support of the laboratory in recent years. This is not intended as a mechanism to acquire "big-ticket" items that may be covered under instrument-specific funding opportunities.

Q.  Can I include a consortium contract for a collaborator?

A. Yes, but such requests must be extremely well justified. NIGMS continues to encourage collaborative and interdisciplinary research when it is appropriate, and individual MIRA grantees are free to collaborate with one another or with other investigators using funds from their individual grants to support their parts of the team's research. A letter from the subcontract PI should be included, making it clear why he or she cannot participate in collaborative research with the PI without support from MIRA.

Q.  Who, if anyone, in addition to the PI should be listed as "key personnel"?

A. Key personnel include any other individuals who contribute to the scientific development or execution of a project in a substantive, measurable way, whether or not they receive salaries or compensation under the grant. Typically, these individuals have doctoral or other professional degrees, although individuals at the master's or baccalaureate level may be considered senior/key personnel if their involvement meets this definition. Consultants and those with a postdoctoral role also may be considered senior/key personnel if they meet this definition. Senior/key personnel must devote measurable effort to the project whether or not salaries or compensation are requested. "Zero percent" effort or "as needed" are not acceptable levels of involvement for those designated as senior/key personnel.

Q.  How will support of other senior/key personnel (co-PIs) be considered?

A. Senior/key personnel who are independent investigators can contribute effort toward MIRA. They may receive support from the award, but only if they do not also receive support from their own MIRA award.

What if they receive support from another NIGMS award that is not a MIRA? 

In that case, they are encouraged to consider applying for MIRA if they are eligible to do so, or become eligible as future MIRA FOAs are issued.

Q.  Who will be the scientific point of contact for my MIRA application?

A. For this initial FOA, Dr. Peter Preusch will serve as the initial scientific point of contact. Once applications are received, they will be referred to the most relevant program official based on internal NIGMS referral procedures and guidelines. The program official assigned to your application should be visible to you in the Commons by the time the application is reviewed and the name and contact information for the program official should appear at the top of the summary statement.

V. Review Information

Q.  How will responses to this FOA be reviewed?

A. Reviews will be by special emphasis panels organized by the NIGMS Office of Scientific Review. The name and contact information for the scientific review official assigned to the application will be posted in the Commons once the assignment has been made.

Q.  What is the timeline for application, review and award?

A. Applications received in May 2015 will be reviewed in October/November 2015 for consideration by the National Advisory General Medical Sciences Council in January 2016, with the earliest possible awards beginning in April 2016.

Q.  Will the reviewers have expertise in the subject area of my application?

A. Yes. NIGMS will ensure that reviewers have the relevant expertise to review the application, bearing in mind that MIRA is intended to support a broad program of research and the breadth of research areas that are encompassed by the NIGMS mission. Thus, reviewers will be expected to bring a broad perspective rather than detailed expertise.

Q.  How will the review process for MIRA differ from that for regular R01 research grant applications?

A. For this FOA, all applications will be discussed. All applicants will receive a summary statement containing the reviewers' critiques, a resume and a summary of the discussion. Reviewers will be asked to provide a single overall impact score and not to provide individual criterion scores. This is intended to shift emphasis away from details of the application and the approach, and to emphasize the potential impact of the investigator's research program on the field. Reviewers will be asked to recommend a budget for work within the investigator's laboratory that is within the mission of NIGMS and is of high scientific merit. They will be asked for guidance on whether the budget should be increased, decreased or stay essentially the same as the level of NIGMS support over the previous several years.

Q.  How do the review criteria differ from those for a regular R01 research grant application?

A. The review criteria are the same, but the wording has been modified to emphasize the review of the investigator's overall NIGMS-relevant research program rather than a specific, narrowly-focused project with highly tailored specific aims. Reviewers should emphasize MIRA-specific aspects of significance, investigator qualifications, innovation, approach and environment.

Q.  How will the study section arrive at a budget recommendation?

A. Reviewers will be asked to consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed work. In answering this question, it is anticipated that reviewers will consider the past productivity of the investigator's laboratory in areas relevant to the NIGMS mission, given the resources at the laboratory's disposal, evidence of efficient use of funds in the past and likelihood of efficient use of funds in the future. They may be asked to consider whether the level of NIGMS support of the laboratory should be increased, decreased or stay about the same, recognizing that in a zero sum game, for everything that goes up, something must go down. Reviewers will not be asked to recommend specific, detailed budget cuts. Rather, they will be asked to recommend an overall budget amount or a budget within one of a few specified ranges still to be determined.

Q.  Can I appeal the review of my MIRA application?

A. No. This FOA is a one-time request for applications that does not offer an opportunity to re-review the application if an appeal were successful. Therefore, be sure to inform NIGMS of any potential reviewer conflicts in a cover letter included with the application at the time of submission.

Q.  If my application for MIRA is not funded, will I be able to prepare a resubmission?

A. No, but you may be eligible to submit a new application to another MIRA FOA in future fiscal years.

Q.  How does the NIGMS $750,000 policy apply to MIRA?

A. NIGMS has a long established policy that entails additional scrutiny of grant applications from investigators whose overall research support including an award for the pending application would exceed $750,000 in direct costs per year. See the NAGMS Council Guidelines for Funding Decisions. MIRA applications from well-funded laboratories will receive special National Advisory General Medical Sciences Council review that includes information and analysis of the total funding of the laboratory, including any projected MIRA funds.

Q.  What will be Council involvement in the second level peer review of MIRA applications?

A. MIRA applications in response to this FOA will be made available to the National Advisory General Medical Sciences Council in the same way as other applications. They will be presented and discussed as a group. Council members will be free to comment on any particular application and then the Council will vote en bloc to approve applications for potential funding with any exceptions noted.

VI. Award Administration Information (Including Funding Restrictions in Section IV.2 of the FOA)

Q.  How will the budget for my MIRA be decided?

A. As for all other awards, the budget will be determined by NIGMS staff by considering the requested budget, the study section recommendation, the National Advisory General Medical Sciences Council recommendation, NIGMS staff analysis of the needs and potential productivity of the program, and the NIGMS budget available in FY 2016. The overall budget for MIRA awards will depend in part on the current funding of the investigators who apply and are approved for conversion of their NIGMS support to MIRA. 

Q.  What will the timeline be for transitioning from current NIGMS grant support to MIRA?

A. This will be determined on a case-by-case basis depending on the expiration dates of existing NIGMS grant awards, unobligated balances on those accounts and the best way to provide a smooth transition. For example, if an investigator has two current grants, one ending in FY 2016 and one ending in FY 2017, and anticipates no significant balance on either award, then the MIRA award may be initiated in FY 2016 when the first grant ends and the budget increased in the second year when the other grant ends.

Q.  How will NIGMS manage the fold-in of current multiple-PI awards and subprojects of multicomponent awards such as P01s and P50s?

A. Investigators who receive a MIRA will be required to relinquish their other NIGMS funding. In the case of multiple-PI awards, they will relinquish their financial interest in the award but will be expected to continue the collaboration with support from MIRA. This transition may be made at the end of a current budget period. The budget of the MIRA would be appropriately adjusted to reflect the cessation of support from the multiple-PI award whenever that occurs. A similar process will be followed for subprojects of P01s and P50s. Investigators supported by MIRA are expected to continue as associated investigators of the continuing P01 or P50 and thus be expected to interact with the other subproject investigators and to have access to the P01 or P50 cores.

Q.  Will a change of PI be allowed?

A. A permanent change of PI will not be allowed, as MIRA is intended to support the research program of a single independent investigator. A temporary change may be allowed with prior approval under circumstances such as sabbatical leave, medical conditions, disability or personal or family situations such as child or eldercare needs.

Q.  What happens if the PI becomes unable to carry out the duties as PI or will be absent for more than 3 months at a time for any reason?

A. Standard NIH and NIGMS policies will be applied.

Q.  Will a change of grantee institution be allowed?

A. Standard NIH and NIGMS policies will be applied.

Q.  What, if anything, will be different about the annual reporting required for MIRA?

A. Annual reports will be required using the Research Performance Progress Report (RPPR). The FOA includes some additional instructions consistent with the broader goals of the research program supported by MIRA and the absence of detailed specific aims. Additional information is requested that relates any new program directions to the NIGMS research mission, discussion of how the work continues to be innovative and of high impact, and the relationship of any new other support to the activities supported by MIRA. 

Q.  What changes will require prior approval?

A. There are no changes to standard NIH policy on prior approval requirements. Prior approval is needed for the following:

  • A change in scope including but not limited to, a change from the approved used of vertebrate animals or involvement of human subjects, select agents or human embryonic stem cells
  • Additional no cost-extensions beyond a first no-cost extension or late notification of an initial no-cost extension
  • Change in status of the PI or senior/key personnel named in the Notice of Award
  • Change in grantee organization or organization status

Q.   How will NIGMS manage overlap with other grants that may be awarded after MIRA?

A. Changes in other support should be reported in the RPPR. The relationship between other support and work supported by MIRA should be explained. NIGMS will assess whether there is sufficient scientific and budgetary overlap to warrant adjustment of the MIRA.

Q.  Will carryover of an unobligated balance from one budget period to another be permitted?

A. Standard NIH and NIGMS policies will be applied.

Q.  Will no-cost extensions be permitted?

A. Standard NIH and NIGMS policies will be applied.

Q.  Will MIRAs be eligible for administrative supplements? Competitive supplements?

A. MIRAs will be eligible for Research Supplements to Promote Diversity in Health-Related Research and other types of administrative supplements, including equipment supplements that may be offered by NIGMS through notices in the NIH Guide for Grants and Contracts. Competitive supplemental applications (revisions) may be accepted in response to FOAs that may be issued in the future to support increases in scope beyond the ability of the investigator to accommodate through reprioritization of their existing resources (e.g., addition of human subjects); however, generally awardees will be expected to reallocate existing resources to accommodate new research directions.

Q.  How will NIGMS handle changes in senior/key personnel on a MIRA?

A. Senior/key personnel named in the notice of award may be replaced or eliminated from the budget with prior approval. Applicants should report such changes in their annual progress reports and should include plans for the utilization of the funds to support the overall effort of the laboratory. Persons not named in the notice of award can be replaced without prior approval.

Q.  How will receipt of support from MIRA effect the eligibility of co-PIs to receive other grants?

A. Senior/key personnel other than the PI may receive support from other awards, including other MIRA awards on which they are also not the PI. Independent investigators who receive any support from more than one NIGMS grant are encouraged to consider consolidating their support by applying for a MIRA application when they become eligible under future FOAs.

Q.  Who will be the program director for MIRA?

A. If I currently have grants with two or more different NIGMS program officials, who will be the program official for my MIRA award and how will that be decided?

This will be resolved by considering the scientific areas included in the MIRA application and NIGMS internal referral guidelines.

VII. Agency Contacts

The agency contacts for the overall program, peer review and grants management are listed in the FOA. PIs may also find it useful to contact the program director who administers their current and other pending NIGMS grant applications and awards.

Program Contact
Peter C. Preusch, Ph.D.
National Institute of General Medical Sciences
Tel: 301-594-0828

Peer Review Contact
Stephanie Constant, Ph.D.
National Institute of General Medical Sciences


Grants Management Contact
Lisa Moeller
National Institute of General Medical Sciences
Tel: 301-594-3914

This page last reviewed on January 09, 2017